iRhythm Q3 revenue $221.6M, up 14.9% YoY; FY2026 revenue guidance raised to $890-895M

iRhythm Holdings, Inc.

Revenue $221.6M vs $192.9M a year ago (+14.9%); gross margin 74.2%, up 310 bps, aided by ~$3.1M one-time tariff refund benefit.
GAAP net loss $29.9M (-$0.90 per diluted share) vs $5.2M loss (-$0.16); adjusted net income $27.8M ($0.82/share) vs $0.06 loss per share.
Adjusted EBITDA $51.2M at 23.1% margin, up $29.6M and 1,190 bps YoY; cash and marketable securities $560.7M as of September 30, 2026.
FY2026 guidance: revenue $890-895M and adjusted EBITDA margin 15.5-16.0%, including ~$16M expected VitalConnect revenue from the Oct 5 close.
VitalConnect acquisition closed October 5, 2026, adding an FDA-cleared mobile cardiac telemetry device; new $300M senior secured revolver closed November 3, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.